https://www.selleckchem.com/products/ABT-869.html
Benefit of chemotherapy for patients with metastatic colorectal cancer is well known, however, that for those patients with poor performance status is little known. We retrospectively evaluated efficacy of chemotherapy with capecitabine and bevacizumab for patients with poor PS (PS 3). Seven patients were included and the median age of the patients was 82 years (range, 65-91 years). The response was not ascertained; nonetheless, the disease control rate was 83.3%. The median PFS and OS were 10.0 and 25.8 months, respectively. Hand foot
Respect!
Kommentar
Delen
